Cytos Biotechnology appoints Itin as CEO

Friday, October 12, 2012 02:29 PM

Cytos Biotechnology, a Swiss biotech company focused on the development of CYT003 in allergic asthma, has appointed Dr. Christian Itin as chief executive officer. The board of directors will propose to the company's shareholders that Itin be elected as member of the board, and it is intended that he will become chairman.

Itin is the former president and CEO of Micromet, a previously Nasdaq-listed biopharmaceutical company, with headquarters in the U.S. and an R&D center in Germany. He led Micromet as CEO from 2004 until its acquisition by Amgen for $1.2 billion in March 2012. In total, Itin has spent 13 years in senior management roles at Micromet. Prior to joining Micromet in 1999, he co-founded Zyomyx, a protein chip company based in Hayward, Calif.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs